Oncology Vol 32 No 6

In this Q&A, we discuss cancer care trends and how the management of cancer is changing as patients live longer.

Late last year, ONCOLOGY hosted a writing contest on Cancer Network, in which we asked our readers to share their personal experiences with delivering bad news. Dr. Trevor Bayliss submitted a piece about his experience as a young patient, and how that influenced his decision to become an oncologist.

Until the superiority of novel agents is proven for all prognostically relevant subgroups of patients with CLL, we believe chemoimmunotherapy continues to have a role.

Elimination of chemotherapy from our combination regimens should be a shared goal among researchers that will move us a step closer to more patient-friendly and scientifically driven therapies for CLL.